ASHBURN, Va. June 25, 2024 In a significant move underscoring its commitment to the rare disease community, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, announces its role as a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference. The event will take place in Albuquerque, New Mexico from June 28-30, 2024.
The FIRST national conference represents a critical convergence point for patients, families, researchers, and healthcare professionals dedicated to understanding and managing ichthyosis and related skin types. As a debilitating genetic disorder, ichthyosis manifests through thick, dry, and scaly skin conditions, significantly impacting patients’ quality of life. FIRST’s biennial gathering provides a vital platform for sharing the latest research, treatment strategies, and emotional support, encapsulating a community spirit that is invaluable for those affected by this challenging condition.
Quoin Pharmaceuticals’ sponsorship underscores its ongoing dedication to rare disease communities. With a portfolio rich in targeted therapeutics aimed at rare skin disorders, the company’s involvement is more than a financial contribution; it signifies a deep alignment with FIRST’s mission of research, advocacy, and education.
The sponsorship will enable a range of critical conference activities, from expert-led panels and workshops to networking sessions that foster collaboration among stakeholders. For the ichthyosis community, this event is not just an assembly but a beacon of hope and a source of much-needed camaraderie.
Supporting the FIRST national conference aligns perfectly with our mission to develop and bring to market innovative treatments for rare and orphan diseases, said Dr. Michael Myers, CEO of Quoin Pharmaceuticals. Our commitment goes beyond drug development; we are dedicated to making a tangible difference in the lives of patients and their families.
Quoin Pharmaceuticals, while still in the clinical stages of its various drug candidates, has made significant strides in understanding and addressing the complexities of rare skin conditions. Their sponsorship of the FIRST 2024 conference is a testament to the company’s holistic approach to patient care combining scientific innovation with a heartfelt dedication to patient communities.
As the 2024 FIRST national conference approaches, the ichthyosis community looks forward to an enriching experience, enhanced by Quoin Pharmaceuticals’ generous support. This partnership not only amplifies the essential efforts of FIRST but also shines a spotlight on the importance of corporate involvement in rare disease advocacy and education.
Comments